Resmed (RSMDF) Receivables (2010 - 2026)

Resmed (RSMDF) has reported Receivables for 17 consecutive years, with $1.1 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 9.52% year-over-year to $1.1 billion; the trailing twelve-month figure through Jun 2026 stood at $1.1 billion (up 9.52% YoY), and the FY2026 full-year result was $1.1 billion, up 9.52% from the prior year.
• Receivables improved to $1.1 billion in Q2 2026 per RSMDF's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Receivables topped out at $1.1 billion in Q2 2026 and bottomed at $534.2 million in Q1 2022.
• Historically, Receivables has averaged $830.8 million across 5 years, with a median of $836.1 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables dropped 3.77% in 2022, then soared 33.31% in 2023.
• Over 5 years, Receivables stood at $695.4 million in 2022, then climbed by 9.91% to $764.3 million in 2023, then grew by 18.66% to $907.0 million in 2024, then rose by 15.45% to $1.0 billion in 2025, then climbed by 3.62% to $1.1 billion in 2026.
• According to Business Quant data, Receivables over the past three periods registered $1.1 billion, $1.0 billion, and $1.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.